Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.

Lindegger N, Sidharta PN, Reseski K, Dingemanse J.

Pulm Pharmacol Ther. 2014 Oct;29(1):41-8. doi: 10.1016/j.pupt.2014.04.007. Epub 2014 May 9.

PMID:
24813561
2.

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.

Shakeri-Nejad K, Aslanis V, Veldandi UK, Mooney L, Pezous N, Brendani B, Juan A, Allison M, Perry R, Legangneux E.

Clin Ther. 2015 Nov 1;37(11):2489-2505.e2. doi: 10.1016/j.clinthera.2015.09.006. Epub 2015 Oct 27.

PMID:
26519230
3.

Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.

Yang H, Laurenza A, Williams B, Patten A, Hussein Z, Ferry J.

Epilepsy Res. 2015 Aug;114:122-30. doi: 10.1016/j.eplepsyres.2015.04.010. Epub 2015 May 1.

4.

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

Matz J, Graff C, Vainio PJ, Kallio A, Højer AM, Struijk JJ, Kanters JK, Andersen MP, Toft E.

Clin Drug Investig. 2011 Nov 1;31(11):799-811. doi: 10.2165/11592950-000000000-00000.

PMID:
21967071
5.

Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.

Ahn LY, Kim SE, Yi S, Dingemanse J, Lim KS, Jang IJ, Yu KS.

Am J Cardiovasc Drugs. 2014 Oct;14(5):377-85. doi: 10.1007/s40256-014-0081-4.

PMID:
24906252
6.

Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.

Stier B, Fossler M, Liu F, Caltabiano S.

Clin Ther. 2015 Jul 1;37(7):1541-54. doi: 10.1016/j.clinthera.2015.05.007. Epub 2015 Jun 29.

PMID:
26138866
7.

Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.

Wang Z, Xuan F, Lin WH, Troyer MD, Tendolkar A, Cutler DL.

Eur J Clin Pharmacol. 2013 Oct;69(10):1761-7. doi: 10.1007/s00228-013-1541-5. Epub 2013 Jul 16.

PMID:
23857248
8.

Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.

Davy M, Upward J, Arumugham T, Twomey C, Chen C, Stier B.

Clin Ther. 2013 Dec;35(12):1964-74. doi: 10.1016/j.clinthera.2013.10.011. Epub 2013 Nov 28.

PMID:
24290737
9.

A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.

Kelleher D, Tombs L, Preece A, Brealey N, Mehta R.

Pulm Pharmacol Ther. 2014 Oct;29(1):49-57. doi: 10.1016/j.pupt.2014.07.002. Epub 2014 Jul 12.

PMID:
25020273
10.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.

Sidharta PN, van Giersbergen PL, Dingemanse J.

J Clin Pharmacol. 2013 Nov;53(11):1131-8. doi: 10.1002/jcph.152. Epub 2013 Sep 4.

PMID:
23900878
11.

Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators..

N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.

12.

Effect of intravenous zanamivir on cardiac repolarization.

Lou Y, Gan J, Peppercorn A, Gould E, Weller S, Piscitelli SC, Patel P.

Pharmacotherapy. 2013 Jul;33(7):701-9. doi: 10.1002/phar.1261. Epub 2013 Apr 3.

PMID:
23553534
13.

Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.

Chen S, Min SS, Peppercorn A, Borland J, Lou Y, Song I, Fujiwara T, Piscitelli SC.

Pharmacotherapy. 2012 Apr;32(4):333-9. doi: 10.1002/j.1875-9114.2012.01033.x. Epub 2012 Mar 15.

PMID:
22422361
14.

Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.

Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A.

Clin Ther. 2008 Feb;30(2):260-70. doi: 10.1016/j.clinthera.2008.02.002.

PMID:
18343264
15.

Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.

de Kam PJ, van Kuijk J, Smeets J, Thomsen T, Peeters P.

Int J Clin Pharmacol Ther. 2012 Aug;50(8):595-604. doi: 10.5414/CP201693.

PMID:
22735462
16.

Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.

Matthys G, Park JW, McGuire S, Wire MB, Zhang J, Bowen C, Williams D, Jenkins JM, Peng B.

Br J Clin Pharmacol. 2010 Jul;70(1):24-33. doi: 10.1111/j.1365-2125.2010.03646.x.

17.

Development of macitentan for the treatment of pulmonary arterial hypertension.

Selej M, Romero AJ, Channick RN, Clozel M.

Ann N Y Acad Sci. 2015 Nov;1358:68-81. doi: 10.1111/nyas.12856. Epub 2015 Aug 20. Review.

PMID:
26291180
18.

Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.

de Kam PJ, van Kuijk J, Prohn M, Thomsen T, Peeters P.

Clin Drug Investig. 2010;30(9):599-611. doi: 10.2165/11537210-000000000-00000.

PMID:
20568829
19.

Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.

Sidharta PN, van Giersbergen PL, Wolzt M, Dingemanse J.

Br J Clin Pharmacol. 2014 Nov;78(5):1035-42. doi: 10.1111/bcp.12447.

20.

Supplemental Content

Support Center